Main Article Content
Introduction: Nocturia is a major problem in men with lower urinary tract symptoms
(LUTS) and Benign Prostatic Hyperplasia (BPH). Transurethral resection of the prostate (TURP) and photoselective vaporization (PVP) have been shown to reduce nocturnal frequency in 32.2% of patients by 0.8 to 1.0 episodes per night, though they carry the risk of operative morbidity. We report on the efficacy of prostatic artery embolization (PAE) in the reduction of nocturia.
Materials & Methods: IRB-approved retrospective study was performed of sixty-eight PAE patients performed in two U.S. centers (Site 1 n=40, Site 2 n=28). American Urological Association symptom index (AUA-SI), quality of life-related symptoms (QoL), nocturnal frequency were evaluated at baseline and at one and three-months. A paired t-test was performed to assess significance.
Results: Baseline demographics demonstrated mean age 64.5 years, AUA-SI 23.9, QoL 4.8, PV 80.6 cc, and Nocturnal Frequency 3.3 episodes. 54.4% (25/46) of patients reported improvement in nocturnal frequency at 1 month and 73.7 % (28/38) at 3 months. Absolute reduction of 0.82 and 1.56 episodes per night were reported at 1 and 3 months (p<0.0001). AUA-SI decreased by 10.0 and 13.4 points at 1 and 3 months (p<0.0001). Quality of Life improved by 2.1 and 2.8 points at 1 and 3 months (p<0.0001). Ten minor self-limiting complications were observed. No major complications were reported.
Conclusions: PAE significantly reduced nocturnal frequency in more than 70% of patients at 3 months.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2) Cornu JN, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, Michel MC, Tubaro A, Madersbacher S. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management: a systematic review and meta-analysis. Eur Urol. 2012 Nov;62(5):877-90.
3) Jin MH, Moon DG. Practical management of nocturia in urology. Indian Journal of Urology : IJU : Journal of the Urological Society of India. 2008;24(3):289-294.
4) Meng E: Sympathetic Hyperactivity in Lower Urinary Tract Dysfunction. Incont Pelvic Floor Dysfunct. 2010, 4: 63-64.
5) Wada N, Numata A, Hou K et al. Nocturia and sleep quality after transurethral resection of the prostate. Int. J. Urol. 2014; 21: 81–85.
6) Yoshimura K, Ohara H, Ichioka K, Terada N, Matsui Y, Terai A, et al. Nocturia and benign prostatic hyperplasia. Urology. 2003;61:786–790.
7) Lee CJ, Cho MC, Ku JH, Kim SW, Paick J-S. Changes in Nocturia after Photoselective Vaporization of the Prostate for Patients with Benign Prostatic Hyperplasia. Korean Journal of Urology. 2010;51(8):531-536.
8) Bagla, S., Cooper, J.M., Rholl, K.S. et al. Early findings from a prospective US trial: prostatic artery embolization (PAE) in the treatment of benign prostatic hypertrophy (BPH). J Vasc Interv Radiol. 2013; 24: S74–S75.
9) Pisco, J.M., Tinto, H.R., Pinheiro, L.C. et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol. 2013; 23: 2561–2572.
10) Carnevale, F.C., da Motta-Leal-Filho, J.M., Antunes, A.A. et al. Quality of life and symptoms relief support prostatic artery embolization for patients with acute urinary retention due to benign prostatic hyperplasia. J Vasc Interv Radiol. 2012; 24: 535–542.
11) Bagla, S., Martin, C.P., van Breda, A. et al. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014; 25: 47–52.
12) McWilliams JP, Kuo MD, Rose SC, Bagla S, Caplin DM, Cohen EI, et al. Society of interventional radiology position statement: prostate artery embolization for treatment of benign disease of the prostate. J Vasc Interv Radiol. 2014;25:1349–51.
13) McVary K, Roehrborn C, Avins A, et al. American Urologic Association: Management of Benign Prostatic Hyperplasia (BPH). American Urologic Association 2010.
14) Sacks D, McClenny TE, Cardella JF, et al. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003; 14:S199-S202.
15) Thomas, A.W., Cannon, A., Bartlett, E. et al. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. J Urol. 2005; 174: 1887–1891.
16) Mebust, W.K., Holtgrewe, H.L., Cockett, A.T., and Peters, P.C. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 2002; 167: 999–1003.
17) Pisco J, Campos Pinheiro L, Bilhim T, Duarte M, Rio Tinto H, Fernandes L, Vaz Santos V, Oliveira AG. Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results. Radiology. 2013 Feb;266(2):668-77.
18) Kaplan SA, Roehrborn CG, McConnell JD, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol. 2008 Sep;180(3):1030-2; discussion 1032-3. doi: 10.1016/j.juro.2008.05.004.
19) Zlotta AR1, Raviv G, Peny MO, Noel JC, Haot J, Schulman CC. Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. J Urol. 1997 Mar;157(3):894-9.